VASCAZEN® POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA PR Newswire WOODBRIDGE, ON, Dec. 17, 2014 WOODBRIDGE...
Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results PR Newswire WOODBRIDGE, ON, Nov. 28, 2014 WOODBRIDGE, ON, Nov...
Pivotal Therapeutics Announces Senior Management Change PR Newswire WOODBRIDGE, ON, Nov. 14, 2014 WOODBRIDGE, ON, Nov. 14, 2014 /PRNewswire/...
Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor PR...
Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN® and...
Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes PR Newswire WOODBRIDGE, ON, Oct. 3, 2014 WOODBRIDGE, ON, Oct...
Pivotal Therapeutics Grants Incentive Stock Options PR Newswire WOODBRIDGE, ON, Sept. 15, 2014 WOODBRIDGE, ON, Sept. 15, 2014 /PRNewswire/...
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In...
Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer PR Newswire WOODBRIDGE, ON...
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014 PR Newswire WOODBRIDGE, Ontario...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.